All-cause mortality of insulin plus dipeptidyl peptidase-4 inhibitors in persons with type 2 diabetes

• Published in: BMC endocrine disorders Vol. 19; no. 1; p. 3
• Main Authors: Yen, Fu-Shun, Chiang, Jen-Huai, Hwu, Chii-Min, Yen, Yu-Hsin, Lin, Boniface J, Wei, James Cheng-Chung, Hsu, Chih-Cheng
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 05.01.2019; BioMed Central; BMC
• Subjects: All-cause mortality; Cohort analysis; Cohort study; Comparative analysis; Diabetes; Diabetes mellitus; Diabetes mellitus (non-insulin dependent); Diabetes therapy; Dipeptidyl-peptidase IV; Glucose; Health; Health insurance; Health risk assessment; Hospitals; Hyperglycemia; Hypoglycemia; Hypoglycemic agents; Insulin; Insurance; Linagliptin; Match; Medical research; Mortality; National health insurance; Online databases; Patients; Peptidase; Saxagliptin; Sitagliptin; Studies; Type 2 diabetes; Taiwan; Cohort study; All-cause mortality; Match
• ISSN: 1472-6823; 1472-6823
• DOI: 10.1186/s12902-018-0330-7

Dipeptidyl peptidase-4 (DPP-4) inhibitors could effectively reduce HbA and postprandial hyperglycemia and could incur only minimal danger of hypoglycemia. Patients with uncontrolled diabetes might be treated by the complementary action of insulin plus DPP-4 inhibitors. Here, we compared the all-cause mortality risk between DPP-4 inhibitor users and nonusers with underlying insulin therapy. Using the population-based National Health Insurance Research Database of Taiwan, we conducted an 11-year retrospective cohort study. A total of 3120 patients undergoing insulin therapy for type 2 diabetes mellitus (T2DM) during 2000-2010 were enrolled. The overall incidence rates for all-cause mortality of 1560 DPP-4 inhibitor users and 1560 matched DPP-4 inhibitor nonusers were compared. No significant difference was found in the baseline demographic and clinical variables of the two groups of patients. Median follow-up period for the matched cohort was 1.67 years. All-cause mortality was observed in 93 (6.0%) of 1560 DPP-4 inhibitor nonusers and 36 (2.3%) of 1560 DPP-4 users. The incidence rate of mortality was 11.72 for DPP-4 inhibitor users and 38.16 per 1000 person-years for DPP-4 inhibitor nonusers. After multivariate adjustment, DPP-4 inhibitor users ran a reduced mortality risk (adjusted hazard ratio 0.32, 95% CI 0.22-0.47; p < 0.0001) than did the nonusers. Risk of all-cause mortality may be reduced when using insulin plus DPP-4 inhibitors than when using insulin plus non-DPP-4 inhibitors.